Exceptional pathologic complete response achieved with androgen deprivation and docetaxel therapy in Gleason 10 prostate cancer

Publication date: Available online 28 January 2019Source: Urology Case ReportsAuthor(s): Ulka Vaishampayan, Dongping Shi, Eman Abdulfatah, Hussein Aoun, Jason WynbergAbstractPathologic complete response is an exceptionally rare occurrence in prostate cancer, especially in the setting of poorly differentiated cancer, with high risk and poor prognostic features. Patient reviewed and signed an informed consent. The case details were collected.Patient had PSA of 52.6 ng/dl and Gleason score 5 + 5 = 10 prostate adenocarcinoma with focal signet ring cell pattern. Genomic testing revealed pathogenic p53 and SPOP mutations. The patient received androgen deprivation therapy and six cycles of docetaxel. His PSA declined to undetectable, and radical prostatectomy (RP) showed no evidence of malignancy. The patient has discontinued all therapy and continues in remission 8 months after surgery.

Source: Urology Case Reports - January 28, 2019 Category: Urology & Nephrology Source Type: research